Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
70.41
-1.40 (-1.95%)
At close: Mar 28, 2025, 4:00 PM
71.41
+1.00 (1.42%)
After-hours: Mar 28, 2025, 6:49 PM EDT
Sarepta Therapeutics Revenue
In the year 2024, Sarepta Therapeutics had annual revenue of $1.90B with 52.97% growth. Sarepta Therapeutics had revenue of $658.41M in the quarter ending December 31, 2024, with 65.94% growth.
Revenue (ttm)
$1.90B
Revenue Growth
+52.97%
P/S Ratio
3.52
Revenue / Employee
$1,386,282
Employees
1,372
Market Cap
6.83B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SRPT News
- 10 hours ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation - Accesswire
- 2 days ago - Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 3 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Investors to Connect - Accesswire
- 4 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation - Accesswire
- 5 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation - Accesswire
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect - Accesswire
- 7 days ago - Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 9 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Stockholders to Learn More About the Investigation - Accesswire